BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium Oct 26, 2020
BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Sep 9, 2020
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update Aug 14, 2020
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast Aug 7, 2020
BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference Aug 6, 2020
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder Jul 20, 2020
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation Jul 9, 2020
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation Jul 7, 2020
